<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:48:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9969383" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9969383</identifier>
        <datestamp>2023-02-28</datestamp>
        <setSpec>phenaturepg</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Drugs Aging</journal-id>
              <journal-id journal-id-type="iso-abbrev">Drugs Aging</journal-id>
              <journal-title-group>
                <journal-title>Drugs &amp; Aging</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1170-229X</issn>
              <issn pub-type="epub">1179-1969</issn>
              <publisher>
                <publisher-name>Springer International Publishing</publisher-name>
                <publisher-loc>Cham</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9969383</article-id>
              <article-id pub-id-type="pmcid">PMC9969383</article-id>
              <article-id pub-id-type="pmc-uid">9969383</article-id>
              <article-id pub-id-type="pmid">36847995</article-id>
              <article-id pub-id-type="pmid">36847995</article-id>
              <article-id pub-id-type="publisher-id">1008</article-id>
              <article-id pub-id-type="doi">10.1007/s40266-023-01008-6</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Mohan</surname>
                    <given-names>Anjana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Majd</surname>
                    <given-names>Zahra</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Michael L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Essien</surname>
                    <given-names>Ekere J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barner</surname>
                    <given-names>Jamie</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Serna</surname>
                    <given-names>Omar</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gallardo</surname>
                    <given-names>Esteban</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fleming</surname>
                    <given-names>Marc L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ordonez</surname>
                    <given-names>Nancy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Holstad</surname>
                    <given-names>Marcia M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Abughosh</surname>
                    <given-names>Susan M.</given-names>
                  </name>
                  <address>
                    <email>smabughosh@uh.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.266436.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1569 9707</institution-id><institution>Department of Pharmaceutical Health Outcomes and Policy, </institution><institution>University of Houston College of Pharmacy, </institution></institution-wrap>4349 Martin Luther King Boulevard, Houston, TX 77204-5047 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.89336.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9924</institution-id><institution>Health Outcomes Division, </institution><institution>The University of Texas at Austin, </institution></institution-wrap>Austin, TX USA </aff>
                <aff id="Aff3"><label>3</label>CareAllies, Houston, TX USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.254024.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9006 1798</institution-id><institution>Pharmaceutical Economics and Policy, </institution><institution>Chapman University School of Pharmacy, </institution></institution-wrap>Irvine, CA USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.266436.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1569 9707</institution-id><institution>Department of Pharmacy Practice and Translational Research, </institution><institution>University of Houston College of Pharmacy, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution>Nell Hodgson Woodruff School of Nursing, </institution><institution>Emory University, </institution></institution-wrap>Atlanta, GA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2023</year>
              </pub-date>
              <volume>40</volume>
              <issue>4</issue>
              <fpage>377</fpage>
              <lpage>390</lpage>
              <history>
                <date date-type="accepted">
                  <day>25</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement>
                <license>
                  <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Hypertension and diabetes mellitus are independent risk factors for cardiovascular diseases. Due to the cardioprotective nature of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), they are recommended for patients with comorbid hypertension and diabetes. However, poor adherence to ACEIs/ARBs among older adults is a major public health concern. This study aimed to assess the effectiveness of a telephonic motivational interviewing (MI) intervention conducted by pharmacy students among a nonadherent older population (â¥ 65 years old) with diabetes and hypertension.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Patients continuously enrolled in a Medicare Advantage Plan who received an ACEI/ARB prescription between July 2017 and December 2017 were identified. Group-based trajectory modeling (GBTM) was used to identify distinct patterns of ACEI/ARB adherence during the 1-year baseline period: adherent, gaps in adherence, gradual decline, and rapid decline in adherence. Patients from the three nonadherent trajectories were randomized into MI intervention or control group. The intervention consisted of an initial call and five follow-up calls administered by MI-trained pharmacy students and tailored to the baseline ACEI/ARB adherence trajectories. The primary outcome was adherence to ACEI/ARB during the 6- and 12-month periods post-MI implementation. The secondary outcome was discontinuation, defined as no refills for ACEI/ARB during the 6- and 12-month periods post-MI implementation. Multivariable regression analyses examined the impact of MI intervention on ACEI/ARB adherence and discontinuation while adjusting for baseline covariates.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">A total of 240 patients in the intervention group and 480 patients as randomly selected controls were included in this study. At 6 months, patients receiving the MI intervention had significantly better adherence (<italic>Î²</italic>Â =Â 0.06; <italic>p</italic>Â =Â 0.03) compared with the controls. Linear and logistic regression models also showed patients in the intervention group were more likely to be adherent than controls within 12 months of intervention implementation (<italic>Î²</italic>Â =Â 0.06; <italic>p</italic>Â =Â 0.02 and OR: 1.46; 95% CI 1.05â2.04, respectively). MI intervention did not have any significant impact on the ACEI/ARB discontinuation.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">Patients who received the MI intervention were more likely to be adherent at 6 and 12 months following the intervention initiation, despite gaps in the follow-up calls due to COVID-19. Pharmacist-led MI intervention is an effective behavioral strategy to improve medication adherence among older adults and tailoring the intervention to past adherence patterns may enhance the intervention effectiveness.</p>
                  <p id="Par5">This study was registered with the United States National Institutes of Health (ClinicalTrials.gov identifier NCT03985098).</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1007/s40266-023-01008-6.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id>
                      <institution>National Heart, Lung, and Blood Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R15HL135700-01A1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>Susan M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© Springer Nature Switzerland AG 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="d32e395">
              <title>Key Points</title>
              <p id="Par6">
                <table-wrap id="Taba">
                  <table frame="hsides" rules="groups">
                    <tbody>
                      <tr>
                        <td align="left">Phone-based motivational interviewing intervention conducted by student pharmacists has a promising effect on improving adherence to antihypertensive medications among the nonadherent older population.</td>
                      </tr>
                      <tr>
                        <td align="left">Tailoring interventions based on past adherence trajectories may enhance intervention effectiveness due to providing more insight into patient behavior.</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </p>
            </sec>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par7">Hypertension frequently coexists with diabetes mellitus and is responsible for 75% of cardiovascular events in the diabetic population as both conditions are recognized as the leading risk factors for heart disease and stroke in the United States [<xref ref-type="bibr" rid="CR1">1</xref>]. Data from The Centers for Disease Control and Prevention (CDC) shows about 877,500 Americans die annually due to cardiovascular diseases (CVD) [<xref ref-type="bibr" rid="CR1">1</xref>]. Approximately 116 million of US adults (47%) have hypertension with only one fourth of those being under control [<xref ref-type="bibr" rid="CR2">2</xref>]. Findings from the National Health and Nutrition Examination Survey (NHANES) conducted between 2015 and 2018 revealed that nearly 60% of patients have uncontrolled blood pressure (â¥ 140/90Â mmÂ Hg) despite being treated with hypertension medications [<xref ref-type="bibr" rid="CR2">2</xref>]. Failure to take medications as prescribed may play a significant role in having poor blood pressure (BP) control [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
              <p id="Par8">Pharmacotherapy of hypertension is critical in patients with diabetes as it is associated with lower risk of cardiovascular events and all-cause mortality [<xref ref-type="bibr" rid="CR4">4</xref>]. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have established benefits for treating hypertension in individuals with diabetes [<xref ref-type="bibr" rid="CR5">5</xref>â<xref ref-type="bibr" rid="CR8">8</xref>]. The beneficial effects go beyond blood pressure control, lowering the risk of micro- and macrovascular adverse events in addition to decreasing all-cause mortality, cardiac morbidity, and mortality [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>â<xref ref-type="bibr" rid="CR12">12</xref>]. However, adherence to antihypertensive medicationsâdefined as the extent to which a patient follows the physicianâs prescription orderâis a common concern [<xref ref-type="bibr" rid="CR13">13</xref>]. Poor medication adherence including failure to initiate the treatment, implement the dosing regimen, or persist on therapy, results in suboptimal BP control and hence higher risk of cardiovascular-related complications, mortality, and healthcare costs [<xref ref-type="bibr" rid="CR14">14</xref>â<xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p id="Par9">Different strategies have been studied to enhance patient adherence to medications used for chronic illnesses. However, a majority of the currently used methods are ineffective and complex [<xref ref-type="bibr" rid="CR18">18</xref>]. Motivational interviewing (MI) is a patient-centered type of counseling which focuses on enhancing self-motivation and commitment to behavior change through a collaborative and supportive communication with a healthcare provider [<xref ref-type="bibr" rid="CR19">19</xref>â<xref ref-type="bibr" rid="CR21">21</xref>]. MI-based interventions have demonstrated promising effects in improving medication adherence across a wide range of chronic conditions [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
              <p id="Par10">In observational studies using pharmacy claims databases, medication possession ratio (MPR) and proportion of days covered (PDC) are common methods for measuring medication adherence. However, in recent years, the use of group-based trajectory modeling (GBTM) has been growing due to the advantages over traditional techniques. Unlike PDC that is calculated as a single number to characterize adherence within a specified time, GBTM creates trajectory groups that incorporate both quantity and timing of medication availability throughout the study period [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. GBTM describes longitudinal patterns of adherence instead of grouping patients as adherent versus nonadherent, which provides invaluable information on patient behavior and underlying barriers to medication adherence. In addition, GBTM creates clusters of patients sharing common characteristics that could better inform the development of tailored interventions for nonadherent individuals [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>â<xref ref-type="bibr" rid="CR29">29</xref>].</p>
              <p id="Par11">This study aimed to examine the effect of a phone-based MI intervention conducted by trained student pharmacists on improving adherence and persistence to ACEIs/ARBs among nonadherent hypertension and diabetes patients enrolled in a Medicare Advantage Plan (MAP). Building upon the prior research, the objective of this study was to tailor the intervention further using adherence trajectories and enhance the intervention effectiveness.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Study Design</title>
                <p id="Par12">This prospective study was conducted among nonadherent patients enrolled in a Texas MAP from July 2016 to July 2021. The MAP provides comprehensive medical/drug coverage, combining all Medicare benefits into one, utilizing a designated network of doctors and hospitals who work together to provide the best care in a cost-effective manner. A previous phase I retrospective study identified nonadherent ACEI/ARB patients using GBTM [<xref ref-type="bibr" rid="CR30">30</xref>]. This phase II prospective study involved conducting an MI intervention among the nonadherent patients identified in the phase I study and was followed-up for 1Â year post-MI implementation. Figure <xref rid="Fig1" ref-type="fig">1</xref> illustrates the study design and timeline. This study was registered with the United States National Institutes of Health (ClinicalTrials.gov identifier NCT03985098).<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design. <italic>GBTM</italic> group-based trajectory modeling</p></caption><graphic xlink:href="40266_2023_1008_Fig1_HTML" id="MO1"/></fig></p>
              </sec>
              <sec id="Sec4">
                <title>Identifying Patients for Telephonic Motivational Interviewing (MI) Intervention</title>
                <p id="Par13">A previous phase I retrospective cohort study identified patients with comorbid hypertension and diabetes mellitus with an ACEI/ARB prescription using the administrative claims data. Patients with an ACEI/ARB refill between July 2017 and December 2017 were included. Patients were also required to be continuously enrolled from July 2016 to December 2018. Patients were excluded from the study if they (a) disenrolled from the health plan, (b) had a diagnosis of dementia between July 2016 and July 2017, or c) had any contraindication for ACEI/ARB use such as angioedema, hyperkalemia, and renal artery stenosis between July 2016 and July 2017. A total of 22,774 patients met the inclusion criteria. Adherence to ACEI/ARB was measured using GBTM, and the model with four distinct trajectories of adherence was identified: adherent, rapid decline in adherence, gaps in adherence, and gradual decline in adherence (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). A total of 7868 patients from the latter three nonadherent trajectories were randomized into the MI intervention and control groups. Of these, 5901 patients were randomized to the intervention group (3:1). Eligible candidates of the intervention group received a brief telephone intervention until a sample size of 250 was reached. Each intervention patient was randomly assigned two controls from the nonadherent cohort.<fig id="Fig2"><label>Fig. 2</label><caption><p>Adherence trajectory groups</p></caption><graphic xlink:href="40266_2023_1008_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par14">G-power 3.1 statistical software estimated that a total of 409 patients would be needed for a two-tailed analysis using logistic regression at a 0.05 Î±-level, 0.10 Î²-level (90% power), and a 1.5 odds ratio. Approximately 230 patients are needed for multiple linear regression analysis with an effect size of 0.10. A total of 500 patients (250 for intervention and control group each) would be needed to have enough power to detect differences at 12 months in case of a 5â7% patient disenrollment from the plan [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>MI Training</title>
                <p id="Par15">A telephone-based MI intervention was implemented by fourth-year pharmacy students (under the supervision of preceptors) who participated in 6-week Advanced Pharmacy Practice Experiences (APPE) rotations at the MAP. The pharmacy students attended a 3-day training session facilitated by an experienced researcher. The MI training included lectures, MI skill demonstration, and guided practice through role-playing. The pharmacy students also had several practice sessions with trained standardized patients. The MI trainer evaluated this practice session to ensure student proficiency in MI skills and MI spirit using a 7-point Likert-type scale (1Â = poor/never to 7Â = excellent/always) [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
              </sec>
              <sec id="Sec6">
                <title>Customization of Intervention</title>
                <p id="Par16">During the phase I retrospective study, the GBTM identified various barriers to adherence like gender, age group 71â75 years, other languages, prevalent statin users, having â¥ 90-day refill, two or more concomitant medications on index date, and presence of comorbidities like myocardial infarction, end-stage renal disease, and depression [<xref ref-type="bibr" rid="CR30">30</xref>]. MI-trained faculty and the MI trainer developed customized education material specific to each of the lower adherence trajectories (rapid decline, gradual decline, gaps in adherence) that could help students during the implementation of MI. The past adherence trajectories further guided the development of strategies to improve patient adherence. Additional adherence barriers were obtained from literature, including forgetfulness, cost, perception about the treatment/disease, regimen complexity, fear of adverse events, pharmacy/physician-related issues, and transportation [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>â<xref ref-type="bibr" rid="CR36">36</xref>]. Finally, a protocol based on the Ask-Provide-Ask approachâa pharmacist adaptation for the Elicit-Provide-Elicit of MIâwas developed for each of the lower adherence trajectories that summarized the customized education that is likely to benefit patients associated with each trajectory [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
              </sec>
              <sec id="Sec7">
                <title>Implementation of Intervention</title>
                <p id="Par17">The MI-trained pharmacy students implemented the MI intervention from May 2019 to March 2021. The intervention consisted of an initial telephonic call followed by five follow-up calls supervised by pharmacy preceptors. The phone-based MI intervention helped reach patients that met the eligibility criteria regardless of their location in Texas, which was advantageous compared with conducting a physical intervention. The recruitment calls were predominantly placed before the COVID-19 pandemic, from May 2019 to February 2020. Only four initial calls were placed during the pandemic from June 2020 to July 2020. Due to the pandemic, there was a gap of four months as pharmacy students could not rotate at the MAP, and the intervention calls were not allowed to be placed outside the MAP due to confidentiality reasons. The first date of the intervention call was the study start date. During the initial call, students obtained informed consent from the patients and asked if they were interested in receiving the intervention. Additionally, the pharmacy students confirmed the diagnosis, the current list of medications, and the refill information. Furthermore, patients were also screened for depression using the Patient Health Questionnaire (PHQ-2)âa validated screening tool for depression [<xref ref-type="bibr" rid="CR38">38</xref>]. Patients identified with depression were requested to schedule an appointment with a healthcare provider to address the issue. MI consistent intervention was provided in English. The MI scripts were adapted from an original script drafted by the MI-trained team of researchers and tailored to the different adherence trajectories determined from the retrospective phase of the study [<xref ref-type="bibr" rid="CR33">33</xref>]. Since MI is a patient-centered approach, the scripts were used as a guide for students through the phone interview process. Students were trained to ask open-ended questions and were encouraged to allow participants to make choices and feel responsible for their decision making. The length of the calls was based on the patientâs need, and an initial call lasted for approximately 15 minutes, while the follow-up calls lasted for approximately 7 minutes. During the follow-up calls, students confirmed if the problem was resolved and provided patient education and positive reinforcement to improve adherence. In some instances, students also contacted the participantâs clinician or pharmacist to resolve any concerns raised by the participant. After each call, students documented the barriers and any concerns that were discussed. To ensure intervention fidelity, 20% of student phone calls were monitored for quality control and adherence to MI<italic>.</italic> The control group received the usual care from the pharmacist, which is the regular refill reminder calls. All the documents collected were deidentified and entered into an Excel sheet for further analysis. The intervention, scripts used for the MI intervention, and data collection were approved by the University of Houston Institutional Review Board.</p>
              </sec>
              <sec id="Sec8">
                <title>Outcome Measures</title>
                <p id="Par18">The primary outcome was the adherence to ACEI/ARB during the 6 and 12 months post-MI implementation. Patients who were continuously enrolled for 1-year post-MI implementation were included. Adherence was calculated from the date of the initial call as it was hypothesized that the effect of intervention will start immediately after an intervention. PDC was used to calculate the adherence to ACEI/ARB, and it represents the total number of medications patients have on hand divided by the entire study period. Patients with a PDC of â¥ 0.80 were considered adherent. Use of the MPR was also considered for the outcome measurement, however, PDC is generally preferred as it is more operationally defined and provides conservative estimates in case of switching and concomitant therapy with multiple drugs within a class [<xref ref-type="bibr" rid="CR39">39</xref>]. For the intervention group, an index date was defined as the initial intervention call date. An index day was assigned for the corresponding controls, which was the first day of the same month of the initial intervention to ensure the same length of follow-up between the controls and intervention. If patients had switched from an ACEI to an ARB or vice versa, then the daysâ supply for both the medications would be summed.</p>
                <p id="Par19">The secondary outcome was discontinuation, defined as no refills for ACEI/ARB during 6 and 12 months after the initial MI implementation call.</p>
              </sec>
              <sec id="Sec9">
                <title>Predictor Variables</title>
                <p id="Par20">All the predictor variables were identified during the previous phase 1 retrospective study. Sex, age (&lt;Â 70 years versus â¥ 70 years), health plan (low-income subsidy versus no low-income subsidy), prescriber specialty (primary care physician versus specialty), refill type (&lt;90 days versus â¥ 90 days), presence of comorbidities like myocardial infarction, end-stage renal disease, depression, congestive heart failure, stroke, and coronary artery disease, number of concomitant medications (â¤Â 2 versus &gt;2), regimen complexity, prevalent users (prevalent versus incident users), prior hospitalizations (none versus â¥ 1), and CMS risk score. Regimen complexity was defined as the mean doses taken per day multiplied by total number of daily medications. Prevalent users were defined as patients who were prescribed ACEIs/ARBs within 6 months prior to the study. The CMS risk score accounted for medication burden and disease severity, and was calculated based on data taken from a large group of beneficiaries to estimate the average predicted costs for each of the components factors (e.g., age, sex, low-income status, individual disease groups). It consists of 189 disease classifications for use in risk adjusting of clinical outcomes in Medicare populations. The detailed definitions of other covariates are published elsewhere [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
              </sec>
              <sec id="Sec10">
                <title>Statistical Analysis</title>
                <p id="Par21">The baseline characteristics were compared between the intervention and control group using chi-square tests for categorical variables and <italic>t</italic>-tests for the continuous variables. A multivariable logistic regression model with PDC as a categorical outcome (PDCÂ â¥ 0.80 versus PDCÂ &lt;Â 0.80) was used to evaluate the effect of intervention on adherence at 6 and 12 months following the intervention initiation. A multiple linear regression modeled PDC as a continuous outcome (ranging from 0 to 1) for 6 and 12 months following the intervention. Finally, a logistic regression model was performed to assess the association between intervention and ACEI/ARB discontinuation during 6- and 12-months post-MI initiation. The major independent variable for all the models were intervention versus control group. Baseline adherence trajectories were controlled in all the models.</p>
              </sec>
              <sec id="Sec11">
                <title>Sensitivity Analysis</title>
                <p id="Par22">Additional analysis was performed by including number of follow-up calls as the primary independent variable. Multiple logistic and linear regression models were performed to evaluate the impact of the number of follow-up calls on adherence. Separate logistic regression model was conducted to examine the impact of number of follow-up calls on discontinuation. All the statistical analysis was conducted using SAS 9.4 at a priori significance of 0.05.</p>
              </sec>
            </sec>
            <sec id="Sec12">
              <title>Results</title>
              <p id="Par23">A total of 22,774 patients with comorbid diabetes and hypertension were identified. Among them, 7868 non-adherent ACEI/ARB patients were randomized to the intervention and control group. Of these, patients were randomized in a 3:1 ratio, resulting in 5901 patients in the intervention group and 1967 patients in the control group. Figure <xref rid="Fig3" ref-type="fig">3</xref> describes the cohort formation flowchart. Of the 5901patients randomized to the intervention group, 2091 patients were outreached. A total of 247 patients agreed to participate in this study. Of them, seven patients were excluded as they were not continuously enrolled. The final intervention cohort was composed of 240 patients, of which 102 were in the âgaps in adherenceâ trajectory group, 94 were in the âgradual declineâ trajectory group, and 44 patients were in the ârapid declineâ trajectory group. The number of patients who successfully completed each of the follow-up calls is as follows: 176 (73.33%) completed the second call, 108 (45%) completed the third call, 70 (29.16%) completed the fourth call, 41 (17.08%) completed the fifth call, and 31 (12.91%) completed the sixth call.<fig id="Fig3"><label>Fig. 3</label><caption><p>Cohort formation</p></caption><graphic xlink:href="40266_2023_1008_Fig3_HTML" id="MO3"/></fig></p>
              <p id="Par24">Of the 1967 patients randomized to the control group, 698 patients were excluded due to disenrollment. Of the remaining 1269 patients, 480 patients were randomly selected for the control group. All the baseline characteristics for 720 patients (240 interventions and 480 controls) are presented in Table <xref rid="Tab1" ref-type="table">1</xref>. Significant differences across congestive heart failure, coronary heart disease, prevalent users, and CMS risk scores were observed between the intervention and control groups.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics of included patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Intervention group (<italic>N</italic>Â =Â 240)<break/>Frequency (%)</th><th align="left">Control group (<italic>N</italic>Â =Â 480)<break/>Frequency (%)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â &lt;Â 70 years</td><td align="left">123 (51.25)</td><td align="left">257 (53.54)</td><td char="." align="char"/></tr><tr><td align="left">Â â¥ 70 years</td><td align="left">117 (48.75)</td><td align="left">223 (46.46)</td><td char="." align="char">0.56</td></tr><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Male</td><td align="left">95 (39.58)</td><td align="left">208 (43.33)</td><td char="." align="char">0.33</td></tr><tr><td align="left">Â Female</td><td align="left">145 (60.42)</td><td align="left">272 (56.67)</td><td char="." align="char"/></tr><tr><td align="left">Health Plan</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Low-income subsidy</td><td align="left">118 (49.17)</td><td align="left">236 (49.17)</td><td char="." align="char"/></tr><tr><td align="left">Â No-subsidy</td><td align="left">122 (50.83)</td><td align="left">244 (50.83)</td><td char="." align="char">1.00</td></tr><tr><td align="left">Prescriber specialty</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â General</td><td align="left">207 (86.25)</td><td align="left">410 (88.36)</td><td char="." align="char"/></tr><tr><td align="left">Â Specialty</td><td align="left">27 (11.25)</td><td align="left">54 (11.64)</td><td char="." align="char">0.96</td></tr><tr><td align="left">Â Missing</td><td align="left">6 (2.50)</td><td align="left">16 (3.33)</td><td char="." align="char"/></tr><tr><td align="left">Myocardial infarction</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes</td><td align="left">4 (1.67)</td><td align="left">10 (2.08)</td><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">236 (98.33)</td><td align="left">470 (97.92)</td><td char="." align="char">0.70</td></tr><tr><td align="left">Depression</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes</td><td align="left">31 (12.92)</td><td align="left">56 (11.67)</td><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">209 (87.08)</td><td align="left">424 (88.33)</td><td char="." align="char">0.62</td></tr><tr><td align="left">Congestive heart failure</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes</td><td align="left">26 (10.83)</td><td align="left">30 (6.25)</td><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">214 (89.17)</td><td align="left">450 (93.75)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Stroke</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes</td><td align="left">10 (4.17)</td><td align="left">18 (3.75)</td><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">230 (95.83)</td><td align="left">462 (96.25)</td><td char="." align="char">0.78</td></tr><tr><td align="left">Coronary artery disease</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes</td><td align="left">63 (26.25)</td><td align="left">92 (19.17)</td><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">177 (73.75)</td><td align="left">388 (80.83)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Refill type</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â &lt;Â 90 days</td><td align="left">26 (10.83)</td><td align="left">55 (11.46)</td><td char="." align="char"/></tr><tr><td align="left">Â â¥ 90 days</td><td align="left">214 (89.17)</td><td align="left">425 (88.54)</td><td char="." align="char">0.80</td></tr><tr><td align="left">Number of other medications on index date</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â â¤Â 2</td><td align="left">169 (70.42)</td><td align="left">340 (70.8.)</td><td char="." align="char"/></tr><tr><td align="left">Â &gt;Â 2</td><td align="left">71 (29.58)</td><td align="left">140 (29.17)</td><td char="." align="char">0.90</td></tr><tr><td align="left">Previous hospitalizations</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 1</td><td align="left">26 (10.83)</td><td align="left">45 (9.38)</td><td char="." align="char"/></tr><tr><td align="left">Â None</td><td align="left">214 (89.17)</td><td align="left">435 (90.63)</td><td char="." align="char">0.53</td></tr><tr><td align="left">Prevalent users</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â No</td><td align="left">25 (10.42)</td><td align="left">90 (18.75)</td><td char="." align="char">0.004</td></tr><tr><td align="left">Â Yes</td><td align="left">215 (89.58)</td><td align="left">390 (81.25)</td><td char="." align="char"/></tr><tr><td align="left">Baseline trajectories</td><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Gaps in adherence</td><td align="left">102 (42.50)</td><td align="left">177 (25.21)</td><td char="." align="char"/></tr><tr><td align="left">Â Gradual decline</td><td align="left">94 (39.17)</td><td align="left">182 (37.92)</td><td char="." align="char">0.09</td></tr><tr><td align="left">Â Rapid decline</td><td align="left">44 (18.33)</td><td align="left">121 (25.21)</td><td char="." align="char"/></tr><tr><td align="left">Â Regimen complexity, mean (SD)</td><td align="left">4.27 (4.32)</td><td align="left">3.86 (3.94)</td><td char="." align="char">0.20</td></tr><tr><td align="left">Â CMS risk score, mean (SD)</td><td align="left">1.50 (0.99)</td><td align="left">1.36 (0.83)</td><td char="." align="char">0.04</td></tr></tbody></table><table-wrap-foot><p><italic>CMS</italic> Centers for Medicare and Medicaid Services, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p>
              <sec id="Sec13">
                <title>Results of the Regression Models at 6 Months</title>
                <p id="Par25">At 6 months, the logistic regression model reported that the MI intervention did not have a significant impact on the adherence to ACEI/ARB (Table <xref rid="Tab2" ref-type="table">2</xref>). Patients associated with the âgaps in adherenceâ trajectories (odds ratio [OR]: 2.61, 95% confidence interval [CI]: 1.69â4.04) or gradual decline in adherence (OR: 1.65, 95% CI 1.06â2.55) were significantly more likely to become adherent as compared with the patients in the ârapid declineâ trajectory (regardless of receiving the intervention or not). Prevalent users were more likely to be adherent compared with incident users (OR: 1.93, 95% CI 1.21â3.09).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Results of logistic regression and linear regression models for 6 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="2">Model I: Logistic regression (adherent vs nonadherent)</th><th align="left" colspan="2">Model II: Linear regression</th></tr><tr><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic>-value</th><th align="left"><italic>Î²</italic> estimate (SE)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Intervention</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.31 (0.94â1.83)</td><td char="." align="char">0.10</td><td char="." align="char">0.06 (0.02)</td><td char="." align="char">0.03</td></tr><tr><td align="left">Previous trajectories</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Gaps in adherence vs rapid decline</td><td char="â" align="char">2.61 (1.69â4.04)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.25 (0.03)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Â Gradual decline vs rapid decline</td><td char="â" align="char">1.65 (1.06â2.55)</td><td char="." align="char">0.02</td><td char="." align="char">0.16 (0.03)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Gender</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Male vs female</td><td char="â" align="char">0.89 (0.65â1.23)</td><td char="." align="char">0.50</td><td char="." align="char">âÂ 0.009 (0.02)</td><td char="." align="char">0.74</td></tr><tr><td align="left">Age (y)</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 70 vs &lt;Â 70</td><td char="â" align="char">0.82 (0.60â1.14)</td><td char="." align="char">0.25</td><td char="." align="char">âÂ 0.31 (0.02)</td><td char="." align="char">0.74</td></tr><tr><td align="left">Health plan</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â No subsidy vs low-income subsidy</td><td char="â" align="char">0.86 (0.62â1.18)</td><td char="." align="char">0.36</td><td char="." align="char">âÂ 0.03 (0.02)</td><td char="." align="char">0.16</td></tr><tr><td align="left">Myocardial infarction</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.01 (0.27â3.82)</td><td char="." align="char">0.98</td><td char="." align="char">0.10 (0.11)</td><td char="." align="char">0.32</td></tr><tr><td align="left">Depression</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.06 (0.65â1.72)</td><td char="." align="char">0.80</td><td char="." align="char">âÂ 0.05 (0.04)</td><td char="." align="char">0.21</td></tr><tr><td align="left">Congestive heart failure</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.22 (0.63â2.36)</td><td char="." align="char">0.55</td><td char="." align="char">0.11 (0.05)</td><td char="." align="char">0.04</td></tr><tr><td align="left">Stroke</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.59 (0.24â1.44)</td><td char="." align="char">0.25</td><td char="." align="char">âÂ 0.04 (0.07)</td><td char="." align="char">0.55</td></tr><tr><td align="left">Coronary artery disease</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.98 (0.64â1.49)</td><td char="." align="char">0.93</td><td char="." align="char">âÂ 0.02 (0.03)</td><td char="." align="char">0.51</td></tr><tr><td align="left">Refill type</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 90 days vs &lt;90 days</td><td char="â" align="char">1.12 (0.66â1.90)</td><td char="." align="char">0.66</td><td char="." align="char">0.03 (0.04)</td><td char="." align="char">0.42</td></tr><tr><td align="left">Number of other medications on index date</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â &gt;Â 2 vs â¤Â 2</td><td char="â" align="char">1.21 (0.75â1.96)</td><td char="." align="char">0.42</td><td char="." align="char">0.01 (0.04)</td><td char="." align="char">0.64</td></tr><tr><td align="left">Previous hospitalizations</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 1 vs none</td><td char="â" align="char">0.68 (0.37â1.24)</td><td char="." align="char">0.21</td><td char="." align="char">âÂ 0.12 (0.05)</td><td char="." align="char">0.01</td></tr><tr><td align="left">Prevalent users</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.93 (1.21â3.09)</td><td char="." align="char">0.005</td><td char="." align="char">0.09 (0.03)</td><td char="." align="char">0.01</td></tr><tr><td align="left">Prescriber specialty</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â General vs specialty</td><td char="â" align="char">0.84 (0.50â1.39)</td><td char="." align="char">0.50</td><td char="." align="char">âÂ 0.04 (0.04)</td><td char="." align="char">0.33</td></tr><tr><td align="left">Â Regimen complexity</td><td char="â" align="char">0.96 (0.91â1.02)</td><td char="." align="char">0.19</td><td char="." align="char">âÂ 0.006 (0.004)</td><td char="." align="char">0.18</td></tr><tr><td align="left">Â CMS risk score</td><td char="â" align="char">1.01 (0.83â1.23)</td><td char="." align="char">0.90</td><td char="." align="char">âÂ 0.01 (0.01)</td><td char="." align="char">0.34</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> confidence interval, <italic>CMS</italic> Centers for Medicare and Medicaid Services, <italic>OR</italic> odds ratio, <italic>SE</italic> standard error</p></table-wrap-foot></table-wrap></p>
                <p id="Par26">The linear regression model determined that MI intervention was significantly associated with better adherence (Î²Â =Â 0.06; <italic>p</italic>Â =Â 0.03). Patients falling into the previous adherence trajectories like gaps in adherence (<italic>Î²</italic>Â =Â 0.25; <italic>p</italic>Â &lt;Â 0.0001) or gradual decline in adherence (<italic>Î²</italic>Â =Â 0.16; <italic>p</italic>Â &lt;Â 0.0001) were positively associated with improved adherence. Patients with congestive heart failure were positively associated with better adherence (<italic>Î²</italic>Â =Â 0.11; <italic>p</italic>Â =Â 0.04). Patients who had one or more previous hospitalizations were less likely to be adherent (<italic>Î²</italic>Â =Â âÂ 0.11; <italic>p</italic>Â =Â 0.01). Finally, prevalent users were more likely to be associated with better adherence (<italic>Î²</italic>Â =Â 0.09; <italic>p</italic>Â =Â 0.01).</p>
                <p id="Par27">Furthermore, compared with the controls, patients receiving the intervention had less ACEI/ARB discontinuation over 6 months following the intervention initiation, and this was marginally significant (OR: 0.64; 95% CI 0.41â1.00). Baseline adherence trajectories like gaps in adherence (OR: 0.14; 95% CI 0.08â0.24) or gradual decline in adherence (OR: 0.34; 95% CI 0.21â0.54) were less likely to be associated with discontinuation of ACEIs/ARBs. Patients with congestive heart failure were less likely to discontinue (OR: 0.23, 95% CI 0.08â0.64). Patients who had one or more hospitalizations were more likely to discontinue ACEI/ARB (OR: 2.56; 95% CI 1.33â4.94) (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of discontinuation logistic regression model for 6 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="2">Discontinuation vs not</th></tr><tr><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Intervention</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.64 (0.41â1.00)</td><td char="." align="char">0.05</td></tr><tr><td align="left">Previous trajectories</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Gaps in adherence vs rapid decline</td><td char="â" align="char">0.14 (0.08â0.24)</td><td char="." align="char">&lt;Â 0.0001</td></tr><tr><td align="left">Â Gradual decline vs rapid decline</td><td char="â" align="char">0.34 (0.21â0.54)</td><td char="." align="char">&lt;Â 0.0001</td></tr><tr><td align="left">Gender</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Male vs female</td><td char="â" align="char">0.98 (0.65â1.47)</td><td char="." align="char">0.93</td></tr><tr><td align="left">Age (y)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 70 vs &lt;Â 70</td><td char="â" align="char">1.20 (0.80â1.80)</td><td char="." align="char">0.37</td></tr><tr><td align="left">Health Plan</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â No subsidy vs low-income subsidy</td><td char="â" align="char">1.17 (0.78â1.76)</td><td char="." align="char">0.43</td></tr><tr><td align="left">Myocardial infarction</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.35 (0.07â1.67)</td><td char="." align="char">0.19</td></tr><tr><td align="left">Depression</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.63 (0.92â2.89)</td><td char="." align="char">0.09</td></tr><tr><td align="left">Congestive heart failure</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.23 (0.08â0.64)</td><td char="." align="char">0.004</td></tr><tr><td align="left">Stroke</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.17 (0.44â3.09)</td><td char="." align="char">0.73</td></tr><tr><td align="left">Coronary artery disease</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.55 (0.94â2.57)</td><td char="." align="char">0.08</td></tr><tr><td align="left">Refill type</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 90 days vs &lt;Â 90 days</td><td char="â" align="char">1.04 (0.55â1.95)</td><td char="." align="char">0.89</td></tr><tr><td align="left">Number of other medications on index date</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â &gt;Â 2 vs â¤Â 2</td><td char="â" align="char">1.08 (0.60â1.94)</td><td char="." align="char">0.79</td></tr><tr><td align="left">Previous hospitalizations</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 1 vs none</td><td char="â" align="char">2.56 (1.33â4.94)</td><td char="." align="char">0.004</td></tr><tr><td align="left">Prevalent users</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.73 (0.43â1.22)</td><td char="." align="char">0.23</td></tr><tr><td align="left">Prescriber specialty</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â General vs specialty</td><td char="â" align="char">1.26 (0.70â2.29)</td><td char="." align="char">0.43</td></tr><tr><td align="left">Â Regimen complexity</td><td char="â" align="char">1.01 (0.94â1.07)</td><td char="." align="char">0.76</td></tr><tr><td align="left">Â CMS risk score</td><td char="â" align="char">1.16 (0.92â1.46)</td><td char="." align="char">0.19</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> confidence interval, <italic>CMS</italic> Centers for Medicare and Medicaid Services, <italic>OR</italic> odds ratio</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec14">
                <title>Results of the Regression Models at 12 Months</title>
                <p id="Par28">Within 12 months of intervention implementation, patients who received the intervention had significantly better adherence to ACEIs/ARBs than controls (OR: 1.46; 95% CI 1.05â2.04) (Table <xref rid="Tab4" ref-type="table">4</xref>). Patients who were in the âgaps in adherenceâ trajectory (OR: 2.65; 95% CI 1.69â4.18) or âgradual declineâ trajectory (OR: 2.19; 95% CI 1.38â3.46) at baseline were more likely to be adherent than the patients in the ârapid declineâ trajectory. Prevalent users were more likely to be adherent than incident users (OR: 1.69; 95% CI 1.05â2.72).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Results of logistic regression and linear regression models for 12 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="2">Model I: Logistic regression (adherent vs nonadherent)</th><th align="left" colspan="2">Model II: Linear regression</th></tr><tr><th align="left">OR (95% CI)</th><th align="left"><italic>p</italic>-value</th><th align="left"><italic>Î²</italic> estimate (SE)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Intervention</td><td char="." align="char"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.46 (1.05â2.04)</td><td char="." align="char">0.02</td><td char="." align="char">0.06 (0.02)</td><td char="." align="char">0.02</td></tr><tr><td align="left">Previous trajectories</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Gaps in adherence vs rapid decline</td><td char="â" align="char">2.65 (1.69â4.18)</td><td char="." align="char">&lt;0.0001</td><td char="." align="char">0.24 (0.03)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Â Gradual decline vs rapid decline</td><td char="â" align="char">2.19 (1.38â3.46)</td><td char="." align="char">0.0008</td><td char="." align="char">0.15 (0.03)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td align="left">Gender</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Male vs female</td><td char="â" align="char">0.88 (0.63â1.22)</td><td char="." align="char">0.46</td><td char="." align="char">âÂ 0.01 (0.02)</td><td char="." align="char">0.67</td></tr><tr><td align="left">Age (y)</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 70 vs &lt;Â 70</td><td char="â" align="char">0.89 (0.65â1.24)</td><td char="." align="char">0.52</td><td char="." align="char">âÂ 0.03 (0.02)</td><td char="." align="char">0.19</td></tr><tr><td align="left">Health Plan</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â No subsidy vs low-income subsidy</td><td char="â" align="char">0.89 (0.64â1.24)</td><td char="." align="char">0.50</td><td char="." align="char">âÂ 0.01 (0.02)</td><td char="." align="char">0.47</td></tr><tr><td align="left">Myocardial infarction</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.03 (0.27â3.88)</td><td char="." align="char">0.96</td><td char="." align="char">0.07 (0.10)</td><td char="." align="char">0.45</td></tr><tr><td align="left">Depression</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">0.78 (0.47â1.29)</td><td char="." align="char">0.34</td><td char="." align="char">âÂ 0.07 (0.03)</td><td char="." align="char">0.05</td></tr><tr><td align="left">Congestive heart failure</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.26 (0.64â2.48)</td><td char="." align="char">0.48</td><td char="." align="char">0.09 (0.05)</td><td char="." align="char">0.07</td></tr><tr><td align="left">Stroke</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.04 (0.44â2.41)</td><td char="." align="char">0.92</td><td char="." align="char">âÂ 0.03 (0.06)</td><td char="." align="char">0.55</td></tr><tr><td align="left">Coronary artery disease</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.08 (0.70â1.65)</td><td char="." align="char">0.71</td><td char="." align="char">âÂ 0.02 (0.03)</td><td char="." align="char">0.44</td></tr><tr><td align="left">Refill type</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 90 days vs &lt;Â 90 days</td><td char="â" align="char">1.13 (0.66â1.94)</td><td char="." align="char">0.64</td><td char="." align="char">0.02 (0.04)</td><td char="." align="char">0.59</td></tr><tr><td align="left">Number of other medications on index date</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â &gt;2 vs â¤Â 2</td><td char="â" align="char">1.24 (0.77â2.02)</td><td char="." align="char">0.36</td><td char="." align="char">0.01 (0.03)</td><td char="." align="char">0.68</td></tr><tr><td align="left">Previous hospitalizations</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â â¥ 1 vs none</td><td char="â" align="char">0.70 (0.38â1.28)</td><td char="." align="char">0.24</td><td char="." align="char">âÂ 0.12 (0.04)</td><td char="." align="char">0.01</td></tr><tr><td align="left">Prevalent users</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â Yes vs no</td><td char="â" align="char">1.69 (1.05â2.72)</td><td char="." align="char">0.02</td><td char="." align="char">0.09 (0.03)</td><td char="." align="char">0.006</td></tr><tr><td align="left">Prescriber specialty</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Â General vs specialty</td><td char="â" align="char">0.64 (0.38â1.10)</td><td char="." align="char">0.11</td><td char="." align="char">âÂ 0.05 (0.04)</td><td char="." align="char">0.18</td></tr><tr><td align="left">Â Regimen complexity</td><td char="â" align="char">0.98 (0.93â1.03)</td><td char="." align="char">0.54</td><td char="." align="char">âÂ 0.003 (0.004)</td><td char="." align="char">0.43</td></tr><tr><td align="left">Â CMS risk score</td><td char="â" align="char">0.90 (0.73â1.10)</td><td char="." align="char">0.33</td><td char="." align="char">âÂ 0.02 (0.01)</td><td char="." align="char">0.06</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> confidence interval, <italic>CMS</italic> Centers for Medicare and Medicaid Services, <italic>OR</italic> odds ratio, <italic>SE</italic> standard error</p></table-wrap-foot></table-wrap></p>
                <p id="Par29">The intervention group was more likely to be adherent at 1Â year after the intervention compared with the control group (<italic>Î²</italic>Â =Â 0.06; <italic>pÂ </italic>=Â 0.02). Similar to the regression model, baseline adherence trajectories (gaps in adherence: <italic>Î²</italic>Â =Â 0.24; <italic>pÂ </italic>&lt;Â 0.0001; gradual decline in adherence: <italic>Î²</italic>Â =Â 0.15; <italic>p</italic>Â &lt;Â 0.0001) and prevalent users (Î²Â =Â 0.09; <italic>p</italic>Â =Â 0.006) were positively associated with better adherence after intervention. Finally, patients with prior hospitalizations were less likely to be adherent after the intervention (<italic>Î²</italic>Â =Â âÂ 0.12; <italic>p</italic>Â =Â 0.01).</p>
                <p id="Par30">At 12 months, MI intervention did not have any significant impact on the discontinuation of ACEI/ARB (see electronic supplementary material [ESM]). Patients with depression, coronary artery disease, and previous hospitalization were more likely to discontinue ACEI/ARB. Patients grouped in the âgaps in adherenceâ trajectory, âgradual declineâ trajectory, congestive heart disease, and prevalent users were less likely to be associated with discontinuation.</p>
              </sec>
              <sec id="Sec15">
                <title>Sensitivity Analysis</title>
                <sec id="Sec16">
                  <title>Results of the Regression Models at 6 Months</title>
                  <p id="Par31">Results of logistic regression for adherence showed that patients receiving three or more follow-up calls were more likely to be adherent (OR: 2.11; 95% CI 1.23â3.61) (see ESM). The linear regression model showed that patients receiving two or more follow-up calls were positively associated with better adherence (<italic>Î²</italic>Â =Â 0.08; <italic>p</italic>Â =Â 0.02). The logistic regression model for discontinuation at 6 months reported that patients receiving three or more follow-up calls were less likely to discontinue (OR: 0.41; 95% CI 0.17â0.97).</p>
                </sec>
                <sec id="Sec17">
                  <title>Results of the Regression Models at 12 Months</title>
                  <p id="Par32">At 12 months post-MI implementation, patients who received two or more follow-up calls were more likely to be adherent (OR: 1.60; 95% CI 1.03â2.49). The same trend was preserved in the linear regression model (<italic>Î²</italic>Â =Â 0.08; <italic>p</italic>Â =Â 0.02). Finally, for the discontinuation outcome, no significant association between the number of calls and discontinuation was observed.</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec18">
              <title>Discussion</title>
              <p id="Par33">The result of this prospective study concludes that a brief MI intervention implemented by pharmacy students among nonadherent ACEI/ARB patients has improved adherence at 1-year post-intervention. These results are consistent with the previous study that documented improved statin adherence among nonadherent patients by implementing MI intervention tailored to prior statin adherence [<xref ref-type="bibr" rid="CR29">29</xref>]. In this current study, the beneficial effects of MI intervention on adherence were preserved even after having a 3- to 4-month gap in placing the intervention calls due to COVID-19. Discontinuation rates after 6 months post-MI intervention were lower, and this trend was marginally significant.</p>
              <p id="Par34">As of 2021, there were 48 million Medicare Part D beneficiaries [<xref ref-type="bibr" rid="CR40">40</xref>], and &gt;Â 70% of antihypertensive users are prescribed an ACEI/ARB [<xref ref-type="bibr" rid="CR41">41</xref>â<xref ref-type="bibr" rid="CR43">43</xref>]. Due to the reno-protective effect of ACEIs/ARBs, they are recommended as the first-line medication among elderly patients with comorbid diabetes and hypertension [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Even after implementing the Centers for Medicare &amp; Medicaid Services (CMS) Star Rating for medication adherence to ACEIs/ARBs, adherence among MAP beneficiaries is still suboptimal and remains an unmet challenge for various stakeholders [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Adherence to ACEI/ARB is one of the quality measures in the CMS Star Rating program, which is used to evaluate health plan performance and is linked to reimbursement [<xref ref-type="bibr" rid="CR47">47</xref>]. According to the Congressional Budget Office, among Medicare (the government health insurance program for individuals 65 years or older) beneficiaries, as the prescription refills increase by 1%, the medical costs fall by 0.2% [<xref ref-type="bibr" rid="CR48">48</xref>]. Among Medicare patients with hypertension, a 1% increase in drug utilization results in the reduction of medical costs (excluding pharmacy costs) by 1.17% [<xref ref-type="bibr" rid="CR49">49</xref>]. In addition, increasing adherence to ACEI/ARB among Medicare beneficiaries has resulted in potential cost savings associated with Medicare Part A and Part B services resulting in lower annual expenditures [<xref ref-type="bibr" rid="CR50">50</xref>]. Medicare beneficiaries adherent to ACEI/ARB had lower healthcare resource utilization than nonadherent patients [<xref ref-type="bibr" rid="CR41">41</xref>]. Hence, our study adds critical knowledge to the growing body of evidence that a customized intervention tailored to past adherence trajectories can improve adherence. Furthermore, the intervention was implemented by MI-trained pharmacy students at no additional cost. Fourth-year pharmacy students have the expertise and knowledge to improve medication adherence. Trained pharmacy students under the supervision of pharmacy preceptors or residents have demonstrated potential in effectively addressing barriers to medication adherence among patients with chronic illness [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR51">51</xref>â<xref ref-type="bibr" rid="CR53">53</xref>]. With the rising physician shortage and healthcare expenditures [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], utilizing trained pharmacy students for disease management is worthwhile [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p>
              <p id="Par35">After 1Â year post-MI implementation, the intervention improved adherence among nonadherent hypertensive patients with diabetes. This may be due to the following reasons:<list list-type="order"><list-item><p id="Par36">The intervention was tailored based on the predictors associated with lower adherence trajectories which were identified in phase I of the study. The major predictors associated with falling into the lower adherence trajectories were being male, refill type, age, having no low-income subsidy, end-stage renal disease, depression, stroke, myocardial infarction, coronary artery disease, number of concomitant medications, prior hospitalizations, and CMS risk score [<xref ref-type="bibr" rid="CR30">30</xref>]. These predictors were incorporated while developing the scripts for MI intervention.</p></list-item><list-item><p id="Par37">Incorporation of customized patient education and individualized self-management activities. Forgetfulness was one of the major barriers that was reported. MI-trained pharmacy students offered potential solutions to improve medication-taking behavior. These included using a pill box, keeping reminders for taking medications, and taking all medications at the same time [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In this study, side effects and regimen complexity were other barriers of adherence [<xref ref-type="bibr" rid="CR31">31</xref>]. Pill burden among patients with multimorbidity is a potential reason for suboptimal adherence [<xref ref-type="bibr" rid="CR30">30</xref>]. Student pharmacists have also played a critical role in collaborating with other healthcare providers to address issues like increased costs, side effects, and regimen complexity [<xref ref-type="bibr" rid="CR56">56</xref>]. Pharmacists educated the intervention group regarding the long-term consequences of nonadherence to antihypertensive medications. Tailored education consistent with adherence patterns in combination with MI have improved adherence.</p></list-item><list-item><p id="Par38">MI intervention may have improved patient motivation, self-efficacy, and hence promoted a favorable and sustainable behavior change. Prior studies have documented that for interventions to be more effective, patients should be given autonomy to make decisions and they should be encouraged to be involved during decision making [<xref ref-type="bibr" rid="CR31">31</xref>]. Pharmacists also played a significant role in positive reinforcement and thus patients felt empowered to follow the medication orders given by physicians [<xref ref-type="bibr" rid="CR57">57</xref>].</p></list-item><list-item><p id="Par39">With better patientâpharmacist interactions, patients may have felt motivated to improve their adherence [<xref ref-type="bibr" rid="CR55">55</xref>]. Pharmacists were trained to provide nonjudgmental reflection to foster adherence. Positive relationships with healthcare providers can have a significant impact on adherence, especially among older adults [<xref ref-type="bibr" rid="CR55">55</xref>]. Since patients interact with their pharmacists more often than with clinicians, pharmacists can educate and give appropriate counseling. These counseling strategies help to maximize patientsâ engagement and reduce their resistance regarding denial of suboptimal adherence [<xref ref-type="bibr" rid="CR55">55</xref>]. Furthermore, these strategies guided them to change their attitudes and beliefs leading to a âgoal settingâ mentality to improve adherence [<xref ref-type="bibr" rid="CR55">55</xref>].</p></list-item><list-item><p id="Par40">The number of follow-up calls and length of intervention may have helped to improve patientsâ perspectives towards adherence. This is consistent with the existing literature that more follow-up calls can help to sustain the behavior change. MI intervention with a higher number of calls was more likely to be effective compared with just one call [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Another prospective study also reported that patients who received two or more calls were more likely to be adherent than those who received fewer than two calls [<xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, the discontinuation rate was also significantly lower among the patients who received two or more follow-up calls [<xref ref-type="bibr" rid="CR32">32</xref>]. Similarly, in this study patients who received two or more follow-up calls were more likely to be adherent.</p></list-item></list></p>
              <p id="Par41">Patients falling into the âgaps in adherenceâ trajectory and âgradual declineâ trajectory were more likely to be adherent and less likely to discontinue ACEI/ARB at 6- and 12-months post-MI implementation than patients falling in the ârapid declineâ trajectory. This is consistent with a prior prospective study that documented patients associated with a ârapid declineâ trajectory were less likely to be adherent and more likely to discontinue statins 6 months after a tailored MI intervention [<xref ref-type="bibr" rid="CR29">29</xref>]. The mean PDC for the ârapid declineâ trajectory was lower than other adherence trajectories. This indicates that adherence barriers associated with a ârapid declineâ trajectory may not have been fully addressed even after incorporating customized interventions, or more frequent calls may be warranted for this group of patients to better connect with the patient. Future studies should evaluate the potential reasons for the rapidly declining adherence pattern.</p>
              <p id="Par42">Prevalent users were more likely to be adherent and less likely to discontinue than incident users. The suboptimal adherence among incident users could be explained by the patientâs beliefs that antihypertensive medication is not needed due to the lack of symptoms. Furthermore, it could also be due to the fear of side effects and lack of awareness regarding the potential future benefits of antihypertensive medications [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Patients with a history of hospitalization were associated with nonadherence and discontinuation, which is in line with prior literature [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Patients with congestive heart failure were more likely to be adherent and less likely to discontinue, which is in concordance with published literature [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
              <sec id="Sec19">
                <title>Limitations</title>
                <p id="Par43">In this study, medications refilled outside the health plan or by paying cash could not be captured. In addition, various sociodemographic factors like race, education, health literacy, and income level were not available. This study could not verify the reason for discontinuation of ACEI/ARB. Since the intervention was in English, Spanish-speaking patients could not be included in the study. Finally, while the initial plan for the intervention was to have monthly follow-up calls, due to the COVID-19 pandemic there were gaps in the intervention, which could have affected the results; other COVID-19-related factors such as the increased isolation and depression that accompanied the pandemic may have impacted the interventionâs effectiveness. It is also worth noting that despite the previous interventions conducted by the health plan for improving ACEI/ARB adherence (as a CMS Star measure), patients included in this study were still nonadherent; this may reflect the level of resistance and how it could impact effectiveness of such interventions among this population. Such interventions by the health plan were not controlled for in this study but were implemented among both controls and intervention patients.</p>
              </sec>
            </sec>
            <sec id="Sec20">
              <title>Conclusion</title>
              <p id="Par44">The findings of this study demonstrate that despite the gaps in the intervention and the unprecedented COVID-19 situation, the customized MI intervention based on prior adherence trajectories improved adherence to ACEIs/ARBs among patients with comorbid hypertension and diabetes at 1Â year. This reveals that a brief telephonic MI intervention may be effective in improving adherence and more research is needed to evaluate sustained behavior change over a longer period of time. Future studies should also develop interventions in other languages such as Spanish so as to improve adherence among racial and ethnic minorities.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Information</title>
              <sec id="Sec21">
                <p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40266_2023_1008_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 20 kb)</p></caption></media></supplementary-material></p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>Anjana Mohan, Zahra Majd have contributed equally to the manuscript.</p>
              </fn>
            </fn-group>
            <notes>
              <title>Declarations</title>
              <notes notes-type="funding">
                <title>Funding</title>
                <p id="Par45">This study was funded by the National Heart, Lung, and Blood Institute (NHLBI), 1R15HL135700-01A1.</p>
              </notes>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Conflict of Interest</title>
                <p id="Par46">SA reports grants from CARsgen and Valeant Pharmaceuticals, outside the submitted work. JB reports personal fees from University of Houston during the conduct of the study and a grant from Centers for Disease Control, Texas Health and Human Services, and Pharmaceutical Research Manufacturers of America Foundation, outside the submitted work. MF reports grants from National Heart, Lung, and Blood Institute and National Institute on Minority Health and Health Disparities (U-54). MF also reports contracts from Texas Health and Human Services Commission and CoI funding on a grant from Texas Council for Developmental Disabilities, outside the submitted work. EG is an employee of CareAllies, a subsidiary of Cigna, outside of the submitted work. The other authors declare that they have no conflict of interest.</p>
              </notes>
              <notes id="FPar2">
                <title>Availability of Data and Material</title>
                <p id="Par47">Not available.</p>
              </notes>
              <notes id="FPar3">
                <title>Ethics Approval</title>
                <p id="Par48">The study was approved by the institutional review board at the University of Houston and is compliant with the Declaration of Helsinki.</p>
              </notes>
              <notes id="FPar4">
                <title>Consent to Participate</title>
                <p id="Par49">Participants receiving the intervention consented verbally over the initial phone call to participation using a script in accordance with all NIH human subject ethical guidelines and the University of Houston IRB requirements for recruitment and informed consent.</p>
              </notes>
              <notes id="FPar5">
                <title>Code Availability</title>
                <p id="Par50">Not available.</p>
              </notes>
              <notes>
                <title>Authorsâ Contributions</title>
                <p id="Par51">Design/conduct of the study (SA, MF, MH); acquisition of subjects and/or data (SA, EG, NO, OS); analysis and interpretation of data (AM, ZM, SA, MJ, JB, EE, MH); preparation of manuscript (AM, ZM, SA). All authors contributed to the review and editing and approved the final manuscript.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Promotion NCfCDPaH. Heart Disease and Stroke. 2022 [cited; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/chronicdisease/resources/publications/factsheets/heart-disease-stroke.htm#:~:text=Leading%20risk%20factors%20for%20heart,unhealthy%20diet%2C%20and%20physical%20inactivity">https://www.cdc.gov/chronicdisease/resources/publications/factsheets/heart-disease-stroke.htm#:~:text=Leading%20risk%20factors%20for%20heart,unhealthy%20diet%2C%20and%20physical%20inactivity</ext-link>. Accessed July 2022.</mixed-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <mixed-citation publication-type="other">(CDC) CfDCaP. Hypertension Cascade: Hypertension Prevalence, Treatment and Control Estimates Among US Adults Aged 18 Years and Older Applying the Criteria From the American College of Cardiology and American Heart Associationâs 2017 Hypertension GuidelineâNHANES 2015â2018. 2021.</mixed-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McLean</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Simpson</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>McAlister</surname>
                      <given-names>FA</given-names>
                    </name>
                    <name>
                      <surname>Tsuyuki</surname>
                      <given-names>RT</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies</article-title>
                  <source>Can J Cardiol</source>
                  <year>2006</year>
                  <volume>22</volume>
                  <issue>10</issue>
                  <fpage>855</fpage>
                  <lpage>860</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0828-282X(06)70304-X</pub-id>
                  <?supplied-pmid 16957803?>
                  <pub-id pub-id-type="pmid">16957803</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Emdin</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Rahimi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Neal</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Callender</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Perkovic</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis</article-title>
                  <source>JAMA</source>
                  <year>2015</year>
                  <volume>313</volume>
                  <issue>6</issue>
                  <fpage>603</fpage>
                  <lpage>615</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2014.18574</pub-id>
                  <?supplied-pmid 25668264?>
                  <pub-id pub-id-type="pmid">25668264</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Deedwania</surname>
                      <given-names>PC</given-names>
                    </name>
                  </person-group>
                  <article-title>Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy</article-title>
                  <source>Cardiol Clin</source>
                  <year>2005</year>
                  <volume>23</volume>
                  <issue>2</issue>
                  <fpage>139</fpage>
                  <lpage>152</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccl.2004.06.006</pub-id>
                  <?supplied-pmid 15694743?>
                  <pub-id pub-id-type="pmid">15694743</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lopez-Jaramillo</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lopez-Lopez</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lopez-Lopez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Alvarez</surname>
                      <given-names>MI</given-names>
                    </name>
                  </person-group>
                  <article-title>The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice</article-title>
                  <source>Diabetol Metab Syndr</source>
                  <year>2014</year>
                  <volume>6</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1186/1758-5996-6-31</pub-id>
                  <pub-id pub-id-type="pmid">24383616</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>Investigators HOPES</collab>
                  </person-group>
                  <article-title>Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy</article-title>
                  <source>The Lancet</source>
                  <year>2000</year>
                  <volume>355</volume>
                  <issue>9200</issue>
                  <fpage>253</fpage>
                  <lpage>259</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(99)12323-7</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yusuf</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sleight</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Pogue</surname>
                      <given-names>Jf</given-names>
                    </name>
                    <name>
                      <surname>Bosch</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Dagenais</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients</article-title>
                  <source>N Engl J Med</source>
                  <year>2000</year>
                  <volume>342</volume>
                  <issue>3</issue>
                  <fpage>145</fpage>
                  <lpage>153</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM200001203420301</pub-id>
                  <?supplied-pmid 10639539?>
                  <pub-id pub-id-type="pmid">10639539</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooke</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Fatodu</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization</article-title>
                  <source>J Manag Care Pharm</source>
                  <year>2006</year>
                  <volume>12</volume>
                  <issue>8</issue>
                  <fpage>649</fpage>
                  <lpage>655</lpage>
                  <?supplied-pmid 17269843?>
                  <pub-id pub-id-type="pmid">17269843</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Adler</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Stratton</surname>
                      <given-names>IM</given-names>
                    </name>
                    <name>
                      <surname>Neil</surname>
                      <given-names>HAW</given-names>
                    </name>
                    <name>
                      <surname>Yudkin</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Matthews</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Cull</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study</article-title>
                  <source>BMJ</source>
                  <year>2000</year>
                  <volume>321</volume>
                  <issue>7258</issue>
                  <fpage>412</fpage>
                  <lpage>419</lpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.321.7258.412</pub-id>
                  <?supplied-pmid 10938049?>
                  <pub-id pub-id-type="pmid">10938049</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Estacio</surname>
                      <given-names>RO</given-names>
                    </name>
                    <name>
                      <surname>Jeffers</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Hiatt</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Biggerstaff</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Gifford</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Schrier</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension</article-title>
                  <source>N Engl J Med</source>
                  <year>1998</year>
                  <volume>338</volume>
                  <issue>10</issue>
                  <fpage>645</fpage>
                  <lpage>652</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM199803053381003</pub-id>
                  <?supplied-pmid 9486993?>
                  <pub-id pub-id-type="pmid">9486993</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Investigators</surname>
                      <given-names>O</given-names>
                    </name>
                  </person-group>
                  <article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events</article-title>
                  <source>N Engl J Med</source>
                  <year>2008</year>
                  <volume>358</volume>
                  <issue>15</issue>
                  <fpage>1547</fpage>
                  <lpage>1559</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa0801317</pub-id>
                  <pub-id pub-id-type="pmid">18378520</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>SabatÃ©</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>SabatÃ©</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <source>Adherence to long-term therapies: evidence for action</source>
                  <year>2003</year>
                  <publisher-name>World Health Organization</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kronish</surname>
                      <given-names>IM</given-names>
                    </name>
                    <name>
                      <surname>Thorpe</surname>
                      <given-names>CT</given-names>
                    </name>
                    <name>
                      <surname>Voils</surname>
                      <given-names>CI</given-names>
                    </name>
                  </person-group>
                  <article-title>Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts</article-title>
                  <source>Transl Behav Med</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <issue>1</issue>
                  <fpage>104</fpage>
                  <lpage>113</lpage>
                  <pub-id pub-id-type="doi">10.1093/tbm/ibz133</pub-id>
                  <?supplied-pmid 31580451?>
                  <pub-id pub-id-type="pmid">31580451</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vrijens</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>De Geest</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Hughes</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Przemyslaw</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Demonceau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ruppar</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A new taxonomy for describing and defining adherence to medications</article-title>
                  <source>Br J Clin Pharmacol</source>
                  <year>2012</year>
                  <volume>73</volume>
                  <issue>5</issue>
                  <fpage>691</fpage>
                  <lpage>705</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04167.x</pub-id>
                  <?supplied-pmid 22486599?>
                  <pub-id pub-id-type="pmid">22486599</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kettani</surname>
                      <given-names>F-Z</given-names>
                    </name>
                    <name>
                      <surname>Dragomir</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>CÃ´tÃ©</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Roy</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>BÃ©rard</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Blais</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention</article-title>
                  <source>Stroke</source>
                  <year>2009</year>
                  <volume>40</volume>
                  <issue>1</issue>
                  <fpage>213</fpage>
                  <lpage>220</lpage>
                  <pub-id pub-id-type="doi">10.1161/STROKEAHA.108.522193</pub-id>
                  <?supplied-pmid 19038916?>
                  <pub-id pub-id-type="pmid">19038916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Degli Esposti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Saragoni</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Benemei</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Batacchi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Geppetti</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Di Bari</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients</article-title>
                  <source>ClinicoEconomics Outcomes Res CEOR.</source>
                  <year>2011</year>
                  <volume>3</volume>
                  <fpage>47</fpage>
                  <lpage>54</lpage>
                  <pub-id pub-id-type="doi">10.2147/CEOR.S15619</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <mixed-citation publication-type="other">Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. 10.1002/14651858.CD000011.pub4.</mixed-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Armstrong</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mottershead</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ronksley</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sigal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hemmelgarn</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Motivational interviewing to improve weight loss in overweight and/or obese patients: a systematic review and meta-analysis of randomized controlled trials</article-title>
                  <source>Obes Rev</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <issue>9</issue>
                  <fpage>709</fpage>
                  <lpage>723</lpage>
                  <?supplied-pmid 21692966?>
                  <pub-id pub-id-type="pmid">21692966</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Rollnick</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <source>Motivational interviewing: Helping people change</source>
                  <year>2012</year>
                  <publisher-name>Guilford Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turner</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Sloan</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Kivlahan</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Haselkorn</surname>
                      <given-names>JK</given-names>
                    </name>
                  </person-group>
                  <article-title>Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis</article-title>
                  <source>Rehabil Psychol</source>
                  <year>2014</year>
                  <volume>59</volume>
                  <issue>2</issue>
                  <fpage>136</fpage>
                  <pub-id pub-id-type="doi">10.1037/a0036322</pub-id>
                  <?supplied-pmid 24708232?>
                  <pub-id pub-id-type="pmid">24708232</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Papus</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dima</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Viprey</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schott</surname>
                      <given-names>A-M</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Novais</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials</article-title>
                  <source>Patient Educ Couns</source>
                  <year>2022</year>
                  <volume>105</volume>
                  <fpage>3186</fpage>
                  <lpage>3203</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pec.2022.06.013</pub-id>
                  <?supplied-pmid 35779984?>
                  <pub-id pub-id-type="pmid">35779984</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Franklin</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Shrank</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Pakes</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>SanfÃ©lix-Gimeno</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Matlin</surname>
                      <given-names>OS</given-names>
                    </name>
                    <name>
                      <surname>Brennan</surname>
                      <given-names>TA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence</article-title>
                  <source>Med care</source>
                  <year>2013</year>
                  <volume>51</volume>
                  <fpage>789</fpage>
                  <lpage>796</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0b013e3182984c1f</pub-id>
                  <?supplied-pmid 23685406?>
                  <pub-id pub-id-type="pmid">23685406</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Franklin</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Krumme</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Tong</surname>
                      <given-names>AY</given-names>
                    </name>
                    <name>
                      <surname>Shrank</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Matlin</surname>
                      <given-names>OS</given-names>
                    </name>
                    <name>
                      <surname>Brennan</surname>
                      <given-names>TA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association between trajectories of statin adherence and subsequent cardiovascular events</article-title>
                  <source>Pharmacoepidemiol Drug Saf</source>
                  <year>2015</year>
                  <volume>24</volume>
                  <issue>10</issue>
                  <fpage>1105</fpage>
                  <lpage>1113</lpage>
                  <pub-id pub-id-type="doi">10.1002/pds.3787</pub-id>
                  <?supplied-pmid 25903307?>
                  <pub-id pub-id-type="pmid">25903307</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vadhariya</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fleming</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Essien</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Esse</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults</article-title>
                  <source>Ame Health Drug Benefits.</source>
                  <year>2019</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>202</fpage>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nagin</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Odgers</surname>
                      <given-names>CL</given-names>
                    </name>
                  </person-group>
                  <article-title>Group-based trajectory modeling in clinical research</article-title>
                  <source>Annu Rev Clin Psychol</source>
                  <year>2010</year>
                  <volume>6</volume>
                  <issue>1</issue>
                  <fpage>109</fpage>
                  <lpage>138</lpage>
                  <pub-id pub-id-type="doi">10.1146/annurev.clinpsy.121208.131413</pub-id>
                  <?supplied-pmid 20192788?>
                  <pub-id pub-id-type="pmid">20192788</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Franklin</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Krumme</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Shrank</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Matlin</surname>
                      <given-names>OS</given-names>
                    </name>
                    <name>
                      <surname>Brennan</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Choudhry</surname>
                      <given-names>NK</given-names>
                    </name>
                  </person-group>
                  <article-title>Predicting adherence trajectory using initial patterns of medication filling</article-title>
                  <source>Am J Manag Care</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <issue>9</issue>
                  <fpage>e537</fpage>
                  <lpage>e544</lpage>
                  <?supplied-pmid 26618441?>
                  <pub-id pub-id-type="pmid">26618441</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lo-Ciganic</surname>
                      <given-names>W-H</given-names>
                    </name>
                    <name>
                      <surname>Donohue</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Perera</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Thorpe</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Thorpe</surname>
                      <given-names>CT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program</article-title>
                  <source>J Gen Intern Med</source>
                  <year>2016</year>
                  <volume>31</volume>
                  <issue>9</issue>
                  <fpage>1052</fpage>
                  <lpage>1060</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11606-016-3747-6</pub-id>
                  <?supplied-pmid 27229000?>
                  <pub-id pub-id-type="pmid">27229000</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Vadhariya</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Essien</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Esse</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2019</year>
                  <volume>25</volume>
                  <issue>10</issue>
                  <fpage>1053</fpage>
                  <lpage>1062</lpage>
                  <?supplied-pmid 31556824?>
                  <pub-id pub-id-type="pmid">31556824</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paranjpe</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Essien</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Barner</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Gallardo</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Group-based trajectory modeling to identify patterns of adherence and its predictors among older adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)</article-title>
                  <source>Patient Prefer Adherence</source>
                  <year>2020</year>
                  <volume>14</volume>
                  <fpage>1935</fpage>
                  <lpage>1947</lpage>
                  <pub-id pub-id-type="doi">10.2147/PPA.S270809</pub-id>
                  <?supplied-pmid 33116437?>
                  <pub-id pub-id-type="pmid">33116437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Henges</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Masilamani</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Essien</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A Pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>63</fpage>
                  <lpage>73</lpage>
                  <?supplied-pmid 27015053?>
                  <pub-id pub-id-type="pmid">27015053</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Esse</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Masilamani</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A motivational interviewing intervention by pharmacy students to improve medication adherence</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2017</year>
                  <volume>23</volume>
                  <issue>5</issue>
                  <fpage>549</fpage>
                  <lpage>560</lpage>
                  <?supplied-pmid 28448784?>
                  <pub-id pub-id-type="pmid">28448784</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Henges</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Masilamani</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>James Essien</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A pharmacist telephone intervention to identify adherence barriers and improve adherence among nonadherent patients with comorbid hypertension and diabetes in a medicare advantage plan</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>63</fpage>
                  <lpage>73</lpage>
                  <?supplied-pmid 27015053?>
                  <pub-id pub-id-type="pmid">27015053</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Der Wal</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Jaarsma</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Moser</surname>
                      <given-names>DK</given-names>
                    </name>
                    <name>
                      <surname>Veeger</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>van Gilst</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>van Veldhuisen</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Compliance in heart failure patients: the importance of knowledge and beliefs</article-title>
                  <source>Eur Heart J</source>
                  <year>2006</year>
                  <volume>27</volume>
                  <issue>4</issue>
                  <fpage>434</fpage>
                  <lpage>440</lpage>
                  <pub-id pub-id-type="doi">10.1093/eurheartj/ehi603</pub-id>
                  <?supplied-pmid 16230302?>
                  <pub-id pub-id-type="pmid">16230302</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Wal</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Jaarsma</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Adherence in heart failure in the elderly: problem and possible solutions</article-title>
                  <source>Int J Cardiol</source>
                  <year>2008</year>
                  <volume>125</volume>
                  <issue>2</issue>
                  <fpage>203</fpage>
                  <lpage>208</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijcard.2007.10.011</pub-id>
                  <?supplied-pmid 18031843?>
                  <pub-id pub-id-type="pmid">18031843</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bohachick</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Burke</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Sereika</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Murali</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dunbar-Jacob</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Adherence to angiotensin-converting enzyme inhibitor therapy for heart failure</article-title>
                  <source>Prog Cardiovasc Nurs</source>
                  <year>2002</year>
                  <volume>17</volume>
                  <issue>4</issue>
                  <fpage>160</fpage>
                  <lpage>166</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.0889-7204.2002.01643.x</pub-id>
                  <?supplied-pmid 12417831?>
                  <pub-id pub-id-type="pmid">12417831</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <mixed-citation publication-type="other">Koh-Knox CP. Motivational interviewing in health care: helping patients change behavior. Am J Pharm Educ. 2009;73(7):127.
</mixed-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maurer</surname>
                      <given-names>DM</given-names>
                    </name>
                  </person-group>
                  <article-title>Screening for depression</article-title>
                  <source>Am Fam Physician</source>
                  <year>2012</year>
                  <volume>85</volume>
                  <issue>2</issue>
                  <fpage>139</fpage>
                  <lpage>144</lpage>
                  <?supplied-pmid 22335214?>
                  <pub-id pub-id-type="pmid">22335214</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nau</surname>
                      <given-names>DP</given-names>
                    </name>
                  </person-group>
                  <source>Proportion of days covered (PDC) as a preferred method of measuring medication adherence</source>
                  <year>2012</year>
                  <publisher-loc>Springfield</publisher-loc>
                  <publisher-name>Pharmacy Quality Alliance</publisher-name>
                  <fpage>25</fpage>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <mixed-citation publication-type="other">Cubanski J, Damico A. Key facts about Medicare Part D enrollment, premiums, and cost sharing in 2021. Kaiser Family Foundation. 2021. <ext-link ext-link-type="uri" xlink:href="https://www.kff.org/medicare/issue-brief/key-facts-about-medicare-part-d-enrollment-premiums-and-cost-sharing-in-2021">https://www.kff.org/medicare/issue-brief/key-facts-about-medicare-part-d-enrollment-premiums-and-cost-sharing-in-2021</ext-link>. Accessed July 2022.</mixed-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Campbell</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Axon</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Pickering</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Black</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hypertension, cholesterol and diabetes medication adherence, health care utilization and expenditure in a Medicare Supplemental sample</article-title>
                  <source>Medicine (Baltimore)</source>
                  <year>2021</year>
                  <volume>100</volume>
                  <issue>35</issue>
                  <fpage>e27143</fpage>
                  <pub-id pub-id-type="doi">10.1097/MD.0000000000027143</pub-id>
                  <?supplied-pmid 34477169?>
                  <pub-id pub-id-type="pmid">34477169</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mohan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Vadhariya</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Majd</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Esse</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Serna</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of a motivational interviewing intervention targeting statins on adherence to concurrent hypertension or diabetes medications</article-title>
                  <source>Patient Educ Couns</source>
                  <year>2021</year>
                  <volume>104</volume>
                  <issue>7</issue>
                  <fpage>1756</fpage>
                  <lpage>1764</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pec.2020.12.009</pub-id>
                  <?supplied-pmid 33402279?>
                  <pub-id pub-id-type="pmid">33402279</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jackson</surname>
                      <given-names>SLNP</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schieb</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antihypertensive and statin medication adherence among medicare beneficiaries</article-title>
                  <source>Am J Prev Med</source>
                  <year>2022</year>
                  <volume>63</volume>
                  <fpage>313</fpage>
                  <lpage>323</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amepre.2022.02.019</pub-id>
                  <?supplied-pmid 35987557?>
                  <pub-id pub-id-type="pmid">35987557</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>American</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>Standards of medical care in diabetesâ2013</article-title>
                  <source>Diabetes Care</source>
                  <year>2013</year>
                  <volume>36</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S11</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc13-S011</pub-id>
                  <pub-id pub-id-type="pmid">23264422</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hou</surname>
                      <given-names>FF</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>GH</given-names>
                    </name>
                    <name>
                      <surname>Xie</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>PY</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>WR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of benazepril for advanced chronic renal insufficiency</article-title>
                  <source>N Engl J Med</source>
                  <year>2006</year>
                  <volume>354</volume>
                  <issue>2</issue>
                  <fpage>131</fpage>
                  <lpage>140</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa053107</pub-id>
                  <?supplied-pmid 16407508?>
                  <pub-id pub-id-type="pmid">16407508</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Majd</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Mohan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Paranjpe</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Abughosh</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Identifying adherent patients to newly initiated statins using previous adherence to chronic medications</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2021</year>
                  <volume>27</volume>
                  <issue>2</issue>
                  <fpage>186</fpage>
                  <lpage>197</lpage>
                  <?supplied-pmid 33506725?>
                  <pub-id pub-id-type="pmid">33506725</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Owen</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Medicare star ratings: Stakeholder proceedings on community pharmacy and managed care partnerships in quality: American Pharmacists Association and Academy of Managed Care Pharmacy</article-title>
                  <source>J Am Pharm Assoc</source>
                  <year>2014</year>
                  <volume>54</volume>
                  <issue>3</issue>
                  <fpage>228</fpage>
                  <lpage>240</lpage>
                  <pub-id pub-id-type="doi">10.1331/JAPhA.2014.13180</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lloyd</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Maresh</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Powers</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Shrank</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Alley</surname>
                      <given-names>DE</given-names>
                    </name>
                  </person-group>
                  <article-title>How much does medication nonadherence cost the medicare fee-for-service program?</article-title>
                  <source>Med Care</source>
                  <year>2019</year>
                  <volume>57</volume>
                  <issue>3</issue>
                  <fpage>218</fpage>
                  <lpage>224</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0000000000001067</pub-id>
                  <?supplied-pmid 30676355?>
                  <pub-id pub-id-type="pmid">30676355</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roebuck</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Medical cost offsets from prescription drug utilization among Medicare beneficiaries</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>10</issue>
                  <fpage>994</fpage>
                  <lpage>995</lpage>
                  <?supplied-pmid 25278321?>
                  <pub-id pub-id-type="pmid">25278321</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lopert</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shoemaker</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Davidoff</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Shaffer</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Abdulhalim</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Lloyd</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Medication adherence and Medicare expenditure among beneficiaries with heart failure</article-title>
                  <source>Am J Manag Care</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <issue>9</issue>
                  <fpage>556</fpage>
                  <lpage>563</lpage>
                  <?supplied-pmid 23009306?>
                  <pub-id pub-id-type="pmid">23009306</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wheat</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Roane</surname>
                      <given-names>TE</given-names>
                    </name>
                    <name>
                      <surname>Connelly</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zeigler</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wallace</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>JH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Using a pharmacist-community health worker collaboration to address medication adherence barriers</article-title>
                  <source>J Am Pharm Assoc (2003)</source>
                  <year>2020</year>
                  <volume>60</volume>
                  <issue>6</issue>
                  <fpage>1009</fpage>
                  <lpage>1014</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.japh.2020.08.021</pub-id>
                  <?supplied-pmid 32943338?>
                  <pub-id pub-id-type="pmid">32943338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stanton-Robinson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Al-Jumaili</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Catney</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Veach</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Witry</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Evaluation of community pharmacist-provided telephone interventions to improve adherence to hypertension and diabetes medications</article-title>
                  <source>J Am Pharm Assoc (2003)</source>
                  <year>2018</year>
                  <volume>58</volume>
                  <issue>4S</issue>
                  <fpage>S20</fpage>
                  <lpage>S24</lpage>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ray</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lokken</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Whyte</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Baumann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oldani</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of a pharmacist-driven, collaborative practice on diabetes management in an Urban underserved population: a mixed method assessment</article-title>
                  <source>J Interprof Care</source>
                  <year>2020</year>
                  <volume>34</volume>
                  <issue>1</issue>
                  <fpage>27</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1080/13561820.2019.1633289</pub-id>
                  <?supplied-pmid 31381470?>
                  <pub-id pub-id-type="pmid">31381470</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <mixed-citation publication-type="other">Heiser S. AAMC report reinforces mounting physician shortage. Association of American Medical Colleges. <ext-link ext-link-type="uri" xlink:href="https://www.aamc.org/news-insights/press-releases/aamc-report-reinforces-mounting-physician-shortage">https://www. aamc. org/news-insights/press-releases/aamc-reportreinforces-mounting-physician-shortage</ext-link>. 2021. Accessed July 2022.</mixed-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holt</surname>
                      <given-names>EW</given-names>
                    </name>
                    <name>
                      <surname>Rung</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Leon</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Firestein</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Krousel-Wood</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>Medication adherence in older adults: a qualitative study</article-title>
                  <source>Educ Gerontol</source>
                  <year>2014</year>
                  <volume>40</volume>
                  <issue>3</issue>
                  <fpage>198</fpage>
                  <lpage>211</lpage>
                  <pub-id pub-id-type="doi">10.1080/03601277.2013.802186</pub-id>
                  <?supplied-pmid 25214707?>
                  <pub-id pub-id-type="pmid">25214707</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Presley</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Groot</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Pavlova</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis</article-title>
                  <source>Res Social Adm Pharm</source>
                  <year>2019</year>
                  <volume>15</volume>
                  <issue>9</issue>
                  <fpage>1057</fpage>
                  <lpage>1067</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.sapharm.2018.09.021</pub-id>
                  <?supplied-pmid 30685443?>
                  <pub-id pub-id-type="pmid">30685443</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <mixed-citation publication-type="other">Albrecht S. The pharmacistâs role in medication adherence. US Pharm. 2011;36(5):45â8.
</mixed-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Menon</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Belue</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wahab</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rugen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kinney</surname>
                      <given-names>AY</given-names>
                    </name>
                    <name>
                      <surname>Maramaldi</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A randomized trial comparing the effect of two phone-based interventions on colorectal cancer screening adherence</article-title>
                  <source>Ann Behav Med</source>
                  <year>2011</year>
                  <volume>42</volume>
                  <issue>3</issue>
                  <fpage>294</fpage>
                  <lpage>303</lpage>
                  <pub-id pub-id-type="doi">10.1007/s12160-011-9291-z</pub-id>
                  <?supplied-pmid 21826576?>
                  <pub-id pub-id-type="pmid">21826576</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kurdi</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Elliott</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Exploring factors associated with patients' adherence to antihypertensive drugs among people with primary hypertension in the United Kingdom</article-title>
                  <source>J Hypertens</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>9</issue>
                  <fpage>1881</fpage>
                  <lpage>1890</lpage>
                  <pub-id pub-id-type="doi">10.1097/HJH.0000000000001382</pub-id>
                  <?supplied-pmid 28441185?>
                  <pub-id pub-id-type="pmid">28441185</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <mixed-citation publication-type="other">Michel B, Brent ME. Adherence in hypertension. Circ Res. 2019;124(7):1124â40.</mixed-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Oh</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Jang</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients</article-title>
                  <source>Hypertens Res</source>
                  <year>2013</year>
                  <volume>36</volume>
                  <issue>11</issue>
                  <fpage>1000</fpage>
                  <lpage>1005</lpage>
                  <pub-id pub-id-type="doi">10.1038/hr.2013.85</pub-id>
                  <?supplied-pmid 23966057?>
                  <pub-id pub-id-type="pmid">23966057</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marcum</surname>
                      <given-names>ZA</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Perera</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Strotmeyer</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Newman</surname>
                      <given-names>AB</given-names>
                    </name>
                    <name>
                      <surname>Simonsick</surname>
                      <given-names>EM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension</article-title>
                  <source>Res Social Adm Pharm</source>
                  <year>2013</year>
                  <volume>9</volume>
                  <issue>6</issue>
                  <fpage>817</fpage>
                  <lpage>827</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.sapharm.2012.12.002</pub-id>
                  <?supplied-pmid 23291338?>
                  <pub-id pub-id-type="pmid">23291338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saadat</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Nikdoust</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Aerab-Sheibani</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bahremand</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Shobeiri</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Saadat</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Adherence to antihypertensives in patients with comorbid condition</article-title>
                  <source>Nephrourol Mon.</source>
                  <year>2015</year>
                  <volume>7</volume>
                  <issue>4</issue>
                  <fpage>e29863</fpage>
                  <pub-id pub-id-type="doi">10.5812/numonthly.29863</pub-id>
                  <?supplied-pmid 26539419?>
                  <pub-id pub-id-type="pmid">26539419</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
